Article citationsMore>>

Tao, K.X., Yin, Y.P., Lin, Y., Li, W., Li, R.D., Liu, W.Z., et al. (2022) Neoadjuvant PD-1 Inhibitor Tislelizumab Combined with S-1 plus Oxaliplatin in Patients with Local Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: Interim Results of a Single-Arm, Phase II Trial. Journal of Clinical Oncology, 40, 300.
https://doi.org/10.1200/JCO.2022.40.4_suppl.300

has been cited by the following article:

• TITLE: Current Status and Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

  AUTHORS: Junjian Liu, Tian Wei, Zhiping Xiang, Yinlu Ding

  KEYWORDS: Locally Advanced Gastric Cancer, Adjuvant Chemotherapy, Neoadjuvant Chemotherapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 30, 2023

  ABSTRACT: Gastric cancer is one of the most common malignant tumours worldwide, with a high degree of malignancy and a poor prognosis. While early gastric cancer can be cured by surgical treatment, locally advanced gastric cancer requires neoadjuvant therapy to shrink the tumour, suppress potential metastases, achieve down-staging, and provide patients with the opportunity for radical surgery to prolong their survival. This article reviews the current status and progress of neoadjuvant chemotherapy for locally advanced gastric cancer.